Molecular glue degraders, known for their ability to break down disease-causing proteins, are gaining traction in clinical development and attracting significant investments from large pharmaceutical companies. Bristol Myers Squibb, Novartis, Eli Lilly, and Roche have invested millions to acquire assets and form partnerships with smaller biotechnology firms focused on developing molecular glues for diseases such as cancer and immunology.
Robert Driscoll, senior vice president of equities research at Wedbush Securities, said the appeal of molecular glues lies in their selectivity and potential to target novel disease mechanisms. “When we look at the market potential of these molecular glues, the ability to potentially tackle undruggable targets unlocks some doors,” Driscoll told BioSpace. “If you have a novel target, you have a real advantage versus other folks out there who will be fast followers. The market potential there is huge.”
Currently, thalidomide and its analogs—manufactured by Bristol Myers Squibb—are the only molecular glues approved by the Food and Drug Administration for multiple myeloma treatment under brand names such as Revlimid, Thalomid, and Pomalyst. Bristol Myers Squibb continues its work in this area with oral therapies like mezigdomide (CC-92480), which showed improvement in progression-free survival when combined with other drugs in a Phase 3 trial for relapsed multiple myeloma patients. Paul Richardson of Dana-Farber’s Jerome Lipper Multiple Myeloma Center said MeziKd “could address a key unmet need” for relapsing patients.
Smaller companies are also making progress. Monte Rosa Therapeutics has secured two licensing agreements with Novartis worth up to $5.7 billion related to its AI-discovered molecular glues targeting immune-mediated conditions; early trials demonstrated over 90% degradation of VAV1 protein along with T cell inhibition effects. C4 Therapeutics has partnered with Roche on degrader-antibody conjugates (DACs) including cemsidomide (CFT-7455), now in Phase 2 trials for multiple myeloma.
Neomorph is conducting Phase 1/2 studies on NEO-811 for clear cell renal cell carcinoma using rational design approaches that allow more targeted drug discovery; it has attracted collaborations from AbbVie, Biogen, and Novo Nordisk involving milestone payments exceeding $1 billion each. Degron Therapeutics’ lead asset DEG6498 entered clinical trials last year targeting advanced solid tumors considered previously undruggable; Takeda signed a deal valued up to $1.2 billion granting access to Degron’s AI-based GlueXplorer platform.
